What it is
Epithalon (also written Epitalon) is a synthetic tetrapeptide with the amino acid sequence Ala-Glu-Asp-Gly (AEDG). It was synthesized from Epithalamin, a polypeptide extract of the bovine pineal gland, and first described by researchers at the St. Petersburg Institute of Bioregulation and Gerontology. It does not occur in this exact four-amino-acid form naturally; it is a synthetic analog developed to replicate the active region of the pineal extract.
What researchers study it for
- Telomere elongation and telomerase activation In vitro studies have examined epithalon's ability to activate telomerase, the enzyme that adds length to telomeres (the protective caps on chromosomes that shorten with each cell division). Work in human fetal fibroblast cultures showed induction of the catalytic subunit of telomerase and measurable telomere elongation. [3] A 2025 study using multiple human cell lines replicated the telomere-lengthening effect and characterized two distinct mechanisms: telomerase upregulation and alternative lengthening of telomeres (ALT). [2]
- Longevity and lifespan in animal models Researchers have studied epithalon in multiple rodent lifespan experiments. In one study using transgenic HER-2/neu mice, monthly subcutaneous administration was associated with a 13.5% increase in average lifespan and reduced incidence of breast adenocarcinomas compared to controls. [4] A separate study in female SHR mice found improved aging biomarkers, including extended estrous function and reduced spontaneous tumor incidence over the animals' natural lifespans. [5]
- Melatonin regulation and circadian function The 2025 review of epithalon describes its relationship to pineal gland function, including effects on melatonin production. Research suggests epithalon may modulate the pineal gland's melatonin output, which declines with age. This mechanism is proposed as one pathway through which the peptide may influence circadian rhythms and aging-related changes in hormonal regulation. [1]
- Antioxidant activity and oxidative stress In vitro work has examined epithalon as an antioxidant agent. A 2025 study using retinal pigment epithelium cells exposed to high-glucose conditions found that epithalon reduced reactive oxygen species (ROS) and improved markers of cellular stress associated with diabetic retinopathy. [6]
- Wound healing and cellular repair The same 2025 retinal cell study also examined epithalon's effect on wound healing rate in an in vitro scratch assay, finding improved wound closure in high-glucose conditions compared to untreated controls. The proposed mechanism involves both antioxidant activity and inhibition of epithelial-to-mesenchymal transition (a cellular process involved in tissue remodeling). [6]
Research context
The evidence base for epithalon is predominantly preclinical. The most-cited work comes from a single Russian research group (Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology), which has produced the majority of published animal and cell studies since the early 2000s. A 2025 comprehensive review acknowledged this history while noting that the telomere-elongation findings have now been independently replicated in human cell lines by a separate research group. [1] [2]
No peer-reviewed human clinical trials for epithalon have been published as of 2026. The animal lifespan studies used rodent models and involved subcutaneous injection protocols over the animals' full lifetimes. The in vitro telomere data, while conducted in human cells, does not translate directly to human outcomes. Researchers evaluating epithalon should weigh the mechanistic interest of the telomere findings against the absence of human safety and efficacy data.
Typical research parameters
| Parameter | Detail |
|---|---|
| Common vial sizes | 5 mg, 10 mg, 20 mg (10 mg and 20 mg most common among vendors) |
| Supplied as | Lyophilized (freeze-dried) powder; requires reconstitution before use |
| Storage (lyophilized) | Refrigerated (2–8°C); some vendors recommend freezer storage for long-term holds |
| Stability (lyophilized) | Typically stable for 12–24 months when stored correctly; check vendor certificate of analysis for lot-specific data |
| Administration studied | Subcutaneous injection (animal studies); intranasal administration also examined in rodent neurological research |
References
- [1] Araj SK, Brzezik J, Mądra-Gackowska K, Szeleszczuk Ł. Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties. International journal of molecular sciences. 2025;26. PubMed ↗
- [2] Al-Dulaimi S, Thomas R, Matta S, Roberts T. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025;26. PubMed ↗
- [3] Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of experimental biology and medicine. 2003;135. PubMed ↗
- [4] Anisimov VN, Khavinson VKh, Alimova IN, Semchenko AV, Yashin AI. Epithalon decelerates aging and suppresses development of breast adenocarcinomas in transgenic her-2/neu mice. Bulletin of experimental biology and medicine. 2002;134. PubMed ↗
- [5] Anisimov VN, Khavinson VKh, Popovich IG, et al. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology. 2003;4. PubMed ↗
- [6] Gatta M, Dovizio M, Milillo C, et al. The Antioxidant Tetrapeptide Epitalon Enhances Delayed Wound Healing in an in Vitro Model of Diabetic Retinopathy. Stem cell reviews and reports. 2025;21. PubMed ↗